These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 18631783)

  • 1. The biology of Huntington's disease.
    Saudou F; Humbert S
    Handb Clin Neurol; 2008; 89():619-29. PubMed ID: 18631783
    [No Abstract]   [Full Text] [Related]  

  • 2. [Mechanisms of neuronal death in Huntington's disease. Second part: therapeutic challenges].
    Bantubungi K; Blum D
    Rev Med Brux; 2007; 28(6):487-94. PubMed ID: 18265808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
    Milnerwood AJ; Kaufman AM; Sepers MD; Gladding CM; Zhang L; Wang L; Fan J; Coquinco A; Qiao JY; Lee H; Wang YT; Cynader M; Raymond LA
    Neurobiol Dis; 2012 Oct; 48(1):40-51. PubMed ID: 22668780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene-environment interactions, neuronal dysfunction and pathological plasticity in Huntington's disease.
    van Dellen A; Grote HE; Hannan AJ
    Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1007-19. PubMed ID: 16445565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HAP1 and intracellular trafficking.
    Li XJ; Li SH
    Trends Pharmacol Sci; 2005 Jan; 26(1):1-3. PubMed ID: 15629196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired ATF6α processing, decreased Rheb and neuronal cell cycle re-entry in Huntington's disease.
    Fernandez-Fernandez MR; Ferrer I; Lucas JJ
    Neurobiol Dis; 2011 Jan; 41(1):23-32. PubMed ID: 20732420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does prothymosin-alpha act as molecular switch between apoptosis and autophagy?
    Piacentini M; Evangelisti C; Mastroberardino PG; Nardacci R; Kroemer G
    Cell Death Differ; 2003 Sep; 10(9):937-9. PubMed ID: 12934067
    [No Abstract]   [Full Text] [Related]  

  • 9. The differential susceptibility of specific neuronal populations: insights from Huntington's disease.
    Mitchell IJ; Griffiths MR
    IUBMB Life; 2003 Jun; 55(6):293-8. PubMed ID: 12938730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyglutamine expansion mutation yields a pathological epitope linked to nucleation of protein aggregate: determinant of Huntington's disease onset.
    Sugaya K; Matsubara S; Kagamihara Y; Kawata A; Hayashi H
    PLoS One; 2007 Jul; 2(7):e635. PubMed ID: 17653262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases.
    Truant R; Atwal RS; Desmond C; Munsie L; Tran T
    FEBS J; 2008 Sep; 275(17):4252-62. PubMed ID: 18637947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropathology of Huntington's disease.
    Vonsattel JP; Keller C; Del Pilar Amaya M
    Handb Clin Neurol; 2008; 89():599-618. PubMed ID: 18631782
    [No Abstract]   [Full Text] [Related]  

  • 13. Neuronal degeneration in striatal transplants and Huntington's disease: potential mechanisms and clinical implications.
    Cicchetti F; Soulet D; Freeman TB
    Brain; 2011 Mar; 134(Pt 3):641-52. PubMed ID: 21278084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell type-specific localization of optineurin in the striatal neurons of mice: implications for neuronal vulnerability in Huntington's disease.
    Okita S; Morigaki R; Koizumi H; Kaji R; Nagahiro S; Goto S
    Neuroscience; 2012 Jan; 202():363-70. PubMed ID: 22155493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Juvenile onset Huntington's disease: correlation with progressive myoclonus epilepsy].
    Sato K; Abe K
    Ryoikibetsu Shokogun Shirizu; 2002; (37 Pt 6):198-200. PubMed ID: 12483860
    [No Abstract]   [Full Text] [Related]  

  • 16. Huntington's disease: new paths to pathogenesis.
    Ross CA
    Cell; 2004 Jul; 118(1):4-7. PubMed ID: 15242639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease.
    Thu DC; Oorschot DE; Tippett LJ; Nana AL; Hogg VM; Synek BJ; Luthi-Carter R; Waldvogel HJ; Faull RL
    Brain; 2010 Apr; 133(Pt 4):1094-110. PubMed ID: 20375136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demise of a neuronal population in Huntington's disease and the importance of hyponeuronogenesis.
    Kremer HP; Kremer GH
    Clin Neurol Neurosurg; 1992; 94 Suppl():S7-8. PubMed ID: 1320524
    [No Abstract]   [Full Text] [Related]  

  • 19. Moving toward a gene therapy for Huntington's disease.
    Glorioso JC; Cohen JB; Carlisle DL; Munoz-Sanjuan I; Friedlander RM
    Gene Ther; 2015 Dec; 22(12):931-3. PubMed ID: 26633828
    [No Abstract]   [Full Text] [Related]  

  • 20. Proliferating neural precursor cells as first step toward neuroregeneration in Huntington's disease?
    Fan MM; Fan J
    J Neurosci; 2006 Dec; 26(52):13411-2. PubMed ID: 17193727
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.